GRI GRI Bio, Inc.
USHealthcareAs of 2026-07-10 16:00
Why GRI matters now
GRI Bio, Inc. (GRI) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.74 with -2.25% on the session and $156.3K in market capitalization; recent performance reads 1-month -15.70% and YTD -72.79%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.0M, and EPS of $-1.61. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -7187.2%.
The latest indexable market news headline is "Asbury Automotive Group Named in TIME America's Best Companies 2026 List" from GuruFocus.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.22
P/S
0.00
EV/EBITDA
0.99
DCF Value
$65.27
FCF Yield
-7187.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-199.5%
ROA
-96.2%
ROIC
-103.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.0M | $-1.61 |
| Q4 2025 | $0.00 | $-2.7M | $-5.34 |
| Q4 2025 | $0.00 | $-2.7M | $-5.34 |
| FY 2025 | $0.00 | $-12.0M | $-121.80 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-1.17
GRI Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutic agents within the United States. Its primary focus lies in addressing inflammatory, fibrotic, and autoimmune disorders. The company's leading drug candidate is GRI-0621, an oral inhibitor targeting type 1 Natural Killer T cells, which is currently undergoing Phase IIa clinical trials. This investigational treatment is being evaluated for severe fibrotic lung conditions, including idiopathic pulmonary fibrosis. Beyond its flagship program, GRI Bio's pipeline also features GRI-0803, a novel oral agonist designed to activate type 2 Natural Killer T cells, currently in preclinical development for autoimmune diseases. Additionally, the company maintains a proprietary library exceeding 500 compounds and includes GRI-0124 and GRI-0729, both aimed at modulating inflammatory immune responses. Founded in 2009 and headquartered in La Jolla, California, GRI Bio, Inc. was previously known as Glycoregimmune, Inc.